Sandoz Group (OTCMKTS:SDZNY) Stock Rating Lowered by Royal Bank of Canada
by Michael Walen · The Markets DailyRoyal Bank of Canada lowered shares of Sandoz Group (OTCMKTS:SDZNY – Free Report) from a moderate buy rating to a hold rating in a research note released on Monday morning, Zacks.com reports.
Sandoz Group Price Performance
Sandoz Group stock opened at $40.78 on Monday. The firm’s 50-day moving average is $41.75 and its 200-day moving average is $36.43. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.86 and a current ratio of 1.33. Sandoz Group has a 1 year low of $25.71 and a 1 year high of $44.98.
Sandoz Group Company Profile
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
See Also
- Five stocks we like better than Sandoz Group
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Stock Analyst Ratings and Canadian Analyst Ratings
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Why Are These Companies Considered Blue Chips?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4